Glycopyrronium Bromide and Formoterol Fumarate Inhalation Aerosol

Glycopyrrolate/formoterol inhalation aerosol) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, to relieve symptoms. Biopodin® Lingchang® uses co-suspension drug delivery technology to deliver glycopyrronium bromide and formoterol, two long-acting bronchodilators.

The results of the PINNACLE-4 study show that compared with single drug, glycopyrrolate/formoterol inhalation aerosol can significantly improve lung function, dyspnea symptoms and patients’ quality of life at the 24th week of treatment. In study PT003011, glycopyrrolate/formoterol inhalation aerosol significantly improved patients’ deep inspiratory capacity (IC) compared with tiotropium at 29 days of treatment. The results of two phase III clinical studies showed that compared with single drug and placebo, glycopyrronium bromide/formoterol inhalation aerosol can take effect quickly within 5 minutes on the first day after taking the medication and significantly improve the results. Lung function in patients with COPD. In addition, after 52 weeks of treatment, the safety profile of glycopyrrolate/formoterol inhalation aerosol was similar to that of glycopyrronium bromide, formoterol and tiotropium bromide, with good safety profile.